Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib in Anti-MAG Antibody Neuropathy
NCT07392229Phase 2Recruiting
- Sponsor
- Azienda Ospedaliero-Universitaria di Padova
- Start
- Mar 2026
- Primary completion
- Mar 2031
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of zanubrutinib, sponsored by Azienda Ospedaliero-Universitaria di Padova. Started Mar 2026; status: recruiting.
02
Drugs
zanubrutinib
Beyond the preview
Go deeper on NCT07392229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07392229.